References
- Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196–204.
- Sethi S. Antibiotics in acute exacerbations of chronic bronchitis. Expert Rev Anti Infect Ther. 2010;8:405–417.
- Budev MM, Wiedemann PH Acute bacterial exacerbation of chronic bronchitis. 2010 [cited: 2016 Nov 1]. Available from: http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/pulmonary/acute-bacterial-exacerbation-chronic-bronchitis
- Nuermberger EL, Bishai WR. Antibiotic resistance in Streptococcus pneumoniae: what does the future hold? Clin Infect Dis. 2004;38(Suppl 4):S363S371.
- Shaikh SB, Ahmed Z, Arsalan SA, et al. Prevalence and resistance pattern of Moraxella catarrhalis in community-acquired lower respiratory tract infections. Infect Drug Resist. 2015;8:263–267.
- Global Initiative for Chronic Obstructive Lung Disease. Pocket guide to COPD diagnosis, management, and prevention. 2015 [cited 1 Nov 2016]. Available from: www.goldcopd.it/materiale/2015/GOLD_Pocket_2015.pdf
- Biedenbach DJ, Bouchillon SK, Hackel M, et al. In vitro activity of gepotidacin, a novel triazaacenaphthylene bacterial topoisomerase inhibitor, against a broad spectrum of bacterial pathogens. Antimicrob Agents Chemother. 2016;60:1918–1923.
- [cited 2016 Nov 1. Available from: http://drugspider.com/trial/index?TrialSearch%5Bdrugname%5D=Gepotidacin&TrialSearch%5Blab_code%5D=GSK-2140944%2C+GSK-2140944E&sort=-interventions
- So W, Crandon JL, Nicolau DP. Pharmacodynamic profile of GSK2140944 against methicillin-resistant Staphylococcus aureus in a murine lung infection model. Antimicrob Agents Chemother. 2015;59:4956–4961.
- Cynamon M, Jureller J, Desai B, et al. In vitro activity of TP-271 against Mycobacterium abscessus, Mycobacterium fortuitum, and Nocardia species. Antimicrob Agents Chemother. 2012;56:3986–3988.
- Grossman HT, Fyfe C, O’ Brien W, et al. The fluorocycline TP-271 is potent against major complicated community-acquired bacterial pneumonia (CABP) pathogens. ECCMID; Switzerland; 2013. Poster number P1641.
- First human patient dosed in trial evaluating novel antibiotic candidate being developed for bacterial respiratory infections with support from National Institute of Allergy and Infectious Diseases. 2016. Available from: http://ir.tphase.com/releasedetail.cfm?releaseid=950670
- Clark RB, Hunt DK, He M, et al. Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy. J Med Chem. 2012;55:606–622.
- A phase 1 study to assess the safety, tolerability and PK of IV TP-271.2015. Available from: https://clinicaltrials.gov/ct2/show/NCT02724085?term=NCT02724085&rank=1
- Farrell JD, Sader SH, Rhomberg RP, et al. In vitro activity of lactone ketolide WCK 4873 when tested against contemporary community-acquired bacterial pneumonia pathogens from a global surveillance program. MICROBE; Boston, MA. 2016. Poster number Sunday-476.
- Study to determine and compare plasma and intrapulmonary concentrations of WCK 4873 in healthy adult human subjects. 2015. Available from: https://clinicaltrials.gov/ct2/show/NCT02453529?term=WCK-4873&rank=1
- Chugh R, Bhatia A, Gupta M, et al. Plasma and intrapulmonary pharmacokinetics of levonadifloxacin in healthy adult subjects. 26th Eur Congress Clin Microbiol Infect Dis (ECCMID); Amsterdam; 2016. Poster number P1267.
- Flamm KR, Farrell JD, Sader SH, et al. In vitro activity of WCK 771, a benzoquinolizine fluoroquinolone (levonadifloxacin) when tested against contemporary gram-positive and -negative bacteria from a global surveillance program. MICROBE; Boston (MA); 2016. Poster number Sunday-456.
- Lahham AA, Souza JN, Patel M, et al. Activity of the new quinolones WCK 771, WCK 1152 and WCK 1153 against clinical isolates of Streptococcus pneumoniae and Streptococcus pyogenes. J Antimicrob Chemother. 2005;56:1130–1133.
- Activity of the new quinolones WCK 771, WCK 1152 and WCK 1153 against clinical isolates of Streptococcus pneumoniae and Streptococcus pyogenes. 2016 Available from: http://wockhardtdiscovery.com/tag/wck-1152
- Kocsis B, Domokos J, Szabo D. Chemical structure and pharmacokinetics ofnovel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin. Ann Clinmicrobiolantimicrob. 2016;15:34.
- Pharmacokinetic profile in plasma and epithelial lining fluid of finafloxacin. 2013 [cited 2016 Nov 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT01907867?term=FINAFLOXACIN&rank=5
- Li CR, Zhai QQ, Wang XK, et al. In vivo antibacterial activity of MRX-I, a new oxazolidinone. Antimicrob Agents Chemother. 2014;58:2418–2421.
- Jeong JW, Jung SJ, Lee HH, et al. In vitro and in vivo activities of LCB01-0371, a new oxazolidinone. Antimicrob Agents Chemother. 2010;54:5359–5362.
- EDP 420. 2016 [cited 2016 Nov 1]. Available from: http://adisinsight.springer.com/drugs/800022584
- EDP 788. 2016. [cited 2016 Nov 1]. Available from: http://adisinsight.springer.com/drugs/800039461
- Posizolid. 2016. [cited 2016 Nov 1]. Available from: http://adisinsight.springer.com/drugs/800013296
- DS 8587. 2016. [cited 2016 Nov 1]. Available from: http://adisinsight.springer.com/drugs/800032713
- de Souza Mendes C, de Souza Antunes AM. Pipeline of known chemical classes of antibiotics. Antibiot (Basel). 2013;2:500–534.
- Oldach D, Clark K, Schranz J, et al. Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia. Antimicrob Agents Chemother. 2013;57:2526–2534.
- A study to evaluate efficacy and safety profile of zabofloxacin tablet 400mg and moxifloxacin tablet 400mg (DW224-III-3). 2014. Available from: https://clinicaltrials.gov/ct2/show/NCT01658020?term=Zabofloxacin&rank=2
- Dong Wha Obtains Approval for Zabolante from MFDS. 2015. Available from: https://www.dong-wha.co.kr/english/customer/dnews/content.asp?t_idx=856